Moreover, patients with CLL had significantly decreased levels of CD19+IgM+IgD+CD38lowCD27+ non-class switched memory B cells 86.63 (91.61 ± 85.96) when compared to the control group 96.83 (99.30-93.69), p = 0.0010 (Fig. 2G). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.